Teduglutide (DrugBank: Teduglutide)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
96 | Crohn disease | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00308438 (ClinicalTrials.gov) | March 1, 2004 | 13/9/2005 | Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008 | An Open Label Extension Study of the Safety and Efficacy of ALX-0600 in Subjects With Crohn's Disease Who Completed the Pilot Study Protocol CL0600-008 | Crohn's Disease | Drug: Teduglutide (ALX-0600) | Shire | NULL | Completed | 18 Years | N/A | All | 67 | Phase 2 | United States;Canada |
2 | NCT00072839 (ClinicalTrials.gov) | October 2003 | 11/11/2003 | Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease | A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects With Moderately Active Crohn's Disease | Crohn's Disease | Drug: ALX-0600;Drug: placebo;Drug: teduglutide 0.05;Drug: teduglutide 0.2 mg;Drug: Teduglutide 0.05 dose;Drug: teduglutide 0.1 mg dose | Shire | NULL | Completed | 18 Years | N/A | Both | 100 | Phase 2 | United States;Canada |